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ABSTRACT: Background: Levodopa-induced dys-
kinesias are a common side effect of dopaminergic therapy
in PD, but their neural correlates remain poorly understood.
Object ives: This study examines whether dyskinesias
are associated with abnormal dopaminergic modulation
of resting-state cortico-striatal connectivity.
Methods: Twelve PD patients with peak-of-dose dyski-
nesias and 12 patients without dyskinesias were withdrawn
from dopaminergic medication. All patients received a sin-
gle dose of fast-acting soluble levodopa and then under-
went resting-state functional magnetic resonance imaging
before any dyskinesias emerged. Levodopa-induced mod-
ulation of cortico-striatal resting-state connectivity was
assessed between the putamen and the following 3 cortical
regions of interest: supplementary motor area, primary sen-
sorimotor cortex, and right inferior frontal gyrus. These
functional connectivity measures were entered into a linear
support vector classifier to predict whether an individual
patient would develop dyskinesias after levodopa intake.
Linear regression analysis was applied to test which con-
nectivity measures would predict dyskinesia severity.
Results : Dopaminergic modulation of resting-state
connectivity between the putamen and primary sensori-
motor cortex in the most affected hemisphere predicted
whether patients would develop dyskinesias with a
specificity of 100% and a sensitivity of 91% (P < .0001).
Modulation of resting-state connectivity between the
supplementary motor area and putamen predicted inter-
individual differences in dyskinesia severity (R2 5 0.627,
P 5 .004). Resting-state connectivity between the right
inferior frontal gyrus and putamen neither predicted
dyskinesia status nor dyskinesia severity.
Conclusions: The results corroborate the notion that
altered dopaminergic modulation of cortico-striatal con-
nectivity plays a key role in the pathophysiology of dys-
kinesias in PD. VC 2016 International Parkinson and
Movement Disorder Society
Key Words: dyskinesias; fMRI; levodopa MRI; Par-
kinson’s disease
Introduction
Levodopa-induced dyskinesias (LID) are a common
and disabling side effect of levodopa treatment of PD.
The main risk factors are disease duration, levodopa
dose, and age at onset.1,2 Yet these factors alone can-
not predict whether an individual patient will develop
LID. Functional magnetic resonance imaging (fMRI) is
a widely used method to study disease-related changes
in functional connectivity while patients are at rest
and without engaging in a specific task.3,4 In PD,
fMRI-based measures of resting-state connectivity can
distinguish patients from healthy controls.5 However,
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it remains unknown whether resting-state fMRI can
identify patients at risk to develop LID or assess the
antidyskinetic effects of novel drugs. Although animal
studies have provided strong evidence for a central
role of the putamen and its cortical projections in
LID,6,7 recent MRI studies have additionally identified
cortical regions playing key roles in the development
of LID comprising the supplementary motor area
(SMA),8-10 primary sensorimotor cortex (SM1),
9,11
and right inferior frontal gyrus (rIFG).8,11,12 In this
study, we employed fMRI to study acute levodopa-
induced changes in cortico-striatal resting-state con-
nectivity in patients with and without peak-of-dose
LID. We hypothesized that patients with LID would
show an altered levodopa-induced modulation of
cortico-striatal connectivity that would predict the
emergence and severity of LID. Based on previous
studies,12,13 we also acquired structural MRI to assess
whether structural changes of these regions would pre-
dict LID.
Methods
Participants
A total of 40 patients with a clinical diagnosis of
PD were enrolled in the study. Exclusion criteria com-
prised (i) tremor-dominant PD, (ii) psychiatric illness,
(iii) dementia, (iv) contraindications to MRI, (v) seda-
tives or serotonergic medication, and (vi) off- or
biphasic dyskinesias. Ten patients were excluded
because they did not tolerate withdrawal of medica-
tion or developed claustrophobia inside the scanner.
Fourteen of the remaining 30 patients had choreiform
peak-of-dose dyskinesias (LID group). All 14 LID
patients underwent structural T1-weighted MRI of the
brain. Two of the 14 patients had to be excluded
from the analysis of resting-state fMRI because they
developed dyskinesias before the first postlevodopa
resting-state fMRI scan (see below). A total of 10 PD
patients without LID (No-LID) participated in both
structural MRI and resting-state fMRI. Of the No-LID
patients, 4 underwent only structural MRI, and in 2
No-LID patients only resting-state fMRI could be
acquired due to technical problems.
The LID and No-LID group were matched regarding
multiple clinical measures (Table 1). Levodopa-
equivalent daily dose14 was higher in the LID patients
(resting-state fMRI study: Puncorrected 5 .031, struc-
tural MRI study: Puncorrected 5 .045). We did not
assess blood levels of levodopa because previous stud-
ies have shown no differences in the pharmacokinetics
of levodopa between patients with and without
LID.15,16 The study was performed in accordance with
the declaration of Helsinki. All patients gave informed
consent to participating in the study, which was
approved by the ethics committee of the Capital
Region of Denmark (study numbers: H-2-2010-146
and H-3-2011-110).
Study Design and MRI Acquisition
An MRI was acquired using a 3 T Verio scanner
(Siemens, Erlangen, Germany) with a 32-channel head
coil. Prior to MRI acquisition, dopaminergic medica-
tion was withdrawn according to 6 half-lives as
described previously.9,10 All MRI scans were acquired
in the morning (see Fig. 1 for an overview). Initially,
we recorded a T1-weighted structural image of the
whole brain (magnetization-prepared rapid gradient
TABLE 1. Overview of clinical and demographic characteristics
Resting-state fMRI study Structural MRI study
LID
(n 5 12)
No-LID
(n 5 12) P
LID
(n 5 14)
No-LID
(n 5 14) P
Gender 6f 4f >.5 7f 5f >.5
Handedness 10r 11r >.5 12r 12r >.5
Age (y) 66.8 6 9.1 67.3 6 6.8 >.5 69.0 6 10.0 64.2 6 9.4 >.1
Education (y) 14.1 6 4.1 13.9 6 3.5 >.5 14.3 6 4.0 13.2 6 3.0 >.1
MMSE 28.9 6 1.8 29.6 6 0.9 >.1 28.9 6 1.7 29.5 6 0.9 >.1
MoCA 27.8 6 2.8 28.6 6 1.1 >.1 27.7 6 2.6 28.7 6 0.8 >.1
BIS-11 59.3 6 8.7 55.0 6 7.7 >.1 58.6 6 8.3 57.1 6 9.5 >.5
Disease duration (y) 7.1 6 3.8 5.9 6 3.4 >.1 8.0 6 4.4 5.9 6 3.4 >.1
LEDD (all) 1014.9 6 407 696.7 6 252 .031a 958.9 6 404 686.4 6 268 .045a
Levodopa (mg) 848.9 6 384 470.9 6 228 .008a 810.9 6 367 504.6 6 288 .021a
LEDD (no levodopa) 166.0 6 118 225.8 6 138 >.1 148.0 6 119 181.8 6 131 >.1
UPDRS-III-OFF 32.2 6 10.7 33.2 6 6.9 >.5 33.1 6 10.4 33.2 6 6.8 >.5
UPDRS-III-ON 19.3 6 7.1 21.3 6 5.3 >.1 20.4 6 7.4 22.3 6 4.1 >.1
D UPDRS-III 12.8 6 5.2 11.9 6 4 >.5 12.7 6 4.8 10.9 6 4.1 >.1
UDysRS (obj.) 14.2 6 7.8 - - 15.6 6 8.3 - -
Gender and handedness were compared using chi-square tests. Age, education, MMSE, MOCA, Barratt Impulsiveness Scale (BIS), disease duration, levodopa
equivalent daily dose (LEDD), and UPDRS were compared using independent-sample t tests. obj., objective, f, female; r, right; y, years.
aPuncorrected < .05.
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echo (MPRAGE), field of view (FOV) 230 mm, slice
thickness 0.9 mm, repetition time (TR) 1900 ms,
echo time (TE) 2.32 ms, flip angle (FA) 98 sagittal ori-
entation). We then acquired fMRI in the practical off
state and subsequently after intake of 200 mg soluble
levodopa 1 50 mg benserazide dissolved in water
(Madopar Quick, La Roche, Basel, Switzerland). We
considered a 200-mg dose of levodopa sufficient even
in patients with long disease duration and high levo-
dopa-equivalent daily dose (LEDD) of their standard
treatment because the clinical response to levodopa is
more pronounced after a washout phase of dopami-
nergic medication than during standard treatment.17,18
Post-levodopa scans were acquired directly after intake
of levodopa and before the emergence of dyskinesias
while dopamine levels were gradually increasing.10
Scans were immediately stopped if a trained clinician
(D.M.H.) inside the scanner room observed develop-
ment of dyskinesias, and the respective fMRI session
was discarded from the analysis. For example, if a
patient developed LID in postlevodopa fMRI run 2,
only the first postlevodopa fMRI run was used for
analysis. This allowed us to assess dopaminergic mod-
ulation of resting-state connectivity without confound-
ing movement artifacts and behavioral differences
between the LID and No-LID group. This was partic-
ularly important because subtle dyskinesias or other
involuntary movements could induce changes in
resting-state networks without necessarily inducing
visible movement artifacts in the MR images. In case
patients did not develop dyskinesias, scans were
stopped after the second postlevodopa fMRI run. The
fMRI measurements comprised interleaved runs of
task-related fMRI (9 min) and resting-state fMRI
(5 min). This design allowed us to control the fram-
ing of the resting state, that is, all patients performed
the same simple motor task before and after acquisi-
tion of resting-state fMRI runs. The procedures and
results related to task-related fMRI have been reported
previously.9,10 In this study, we significantly extend
these previous reports by investigating whether differen-
ces in neural connectivity can distinguish patients with
and without LID even in the absence of a motor task.
An advantage of this would be that fMRI acquisition
would be easier to standardize and apply in clinical set-
tings. To prevent patients from falling asleep during the
resting-state fMRI, patients were instructed to remain
still with eyes open while watching a gray screen. Each
resting-state fMRI session comprised 160 T2*-weighted
echo planar images (FOV 192 mm, slice thickness 3.5
mm, slice spacing 0.2 mm, TR 1850 ms, TE 26 ms, FA
758, 36 slices with whole brain coverage).
Data Analysis of Resting-State fMRI
Analyses were conducted using Statistical Parametric
Mapping (SPM 8 rev.4667, Wellcome Trust Centre
for Neuroimaging, London, UK). Standard preprocess-
ing procedures comprised accounting for T1-
equilibrium effects, realignment, correction for nui-
sance variables (respiration and cardiac pulsation, sig-
nals from white matter and cerebrospinal fluid,
residual movement artefacts), normalization to stereo-
tactic space using the Montreal Neurological Institute
template, and smoothing with an isotropic Gaussian
kernel at 8 mm full-width at half maximum. The fol-
lowing steps were then conducted using a priori
defined regions of interest (ROIs) using anatomical
masks19 to avoid circularity when constraining the
selected regions to the studied patient group.20 ROIs
comprised the bilateral putamen and bilateral SM1
(BA 1-4) as well as the SMA (bilateral BA 6) based on
previous work.9,10 The anatomical SMA mask com-
prised preSMA and SMA.21 In addition, we included
rIFG based on recent work by Cerasa and colleagues
on the neural correlates of LID.8,11,12 Because the pre-
viously reported rIFG coordinates varied along the
anterior–posterior axis, we included both BA 44 and
45. For each patient, the time course of blood-oxygen-
level dependent (BOLD) fluctuations from the right and
left putamen were extracted using the first eigenvariate
and used as regressors in separate general linear model
(GLMs) applying a band-pass filter between 0.008 and
0.1 Hz.3 Thus, the estimated beta weights reflected to
what extent the BOLD time course in a given voxel
covaried with the BOLD time course in the putamen
constituting a measure of functional connectivity (covari-
ance). Regional beta weights were extracted from (i and
ii) the right and left SM1, (iii) the SMA, and (iv) the
rIFG using the first eigenvariate from the unthresholded
SPM of all voxels corresponding to the respective region.
For resting-state connectivity between the SM1 and
putamen, we extracted parameters from the most and
less affected hemisphere, respectively, for each patient.
Importantly, lateralization of predominant motor
symptoms was equally distributed in the LID and No-
LID group (resting-state fMRI: P > .5; structural
MRI: P > .5, chi-square tests). Because previously
reported SMA activation in LID patients comprised a
FIG. 1. Study design. Structural scans (sMRI) were acquired in the off
state. Resting-state fMRI (RS-fMRI) was recorded in the off-
medication state and repeatedly after levodopa intake (first vertical
dashed line) until dyskinesias emerged (second vertical dashed line).
[Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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midline cluster extending into both hemispheres8-10
and IFG activation was mainly right lateralized,8,11,13
we refrained from extracting resting-state connectivity
values from the most and less affected hemisphere to
avoid modeling interhemispheric connectivity (eg, left
putamen to rIFG) in some patients and intrahemi-
spheric connectivity (eg, right putamen to rIFG) in
other patients. Instead, we used the right putamen for
modeling rIFG–putamen connectivity and the mean of
left and right putamen–SMA connectivity. Of note, con-
nectivity parameters from these cortical ROIs to the left
and right putamen, respectively, were highly correlated
(P < .001, Pearson correlation). We computed dopami-
nergic modulation of resting-state connectivity by sub-
tracting the baseline measure in the off-medication state
from the postlevodopa measure. These parameters were
transformed into z scores for further analyses (see
below). Z-scoring was done for each resting-state con-
nectivity measure (eg, SMA–putamen) for the whole
group (LID and No-LID patients together, n 5 24) by
subtracting the mean and dividing by the standard devia-
tion, that is, it normalized the data to a mean of 0 and
a standard deviation of 1. The results did not change
when data were not z-transformed (not shown).
To test whether regions outside the considered ROIs
showed an abnormal levodopa-induced modulation of
connectivity with the putamen, we also conducted a 2
3 2 analysis of variance using Group (LID and No-
LID) and Dopamine (postlevodopa and OFF) as main
effects and tested for a Group 3 Dopamine interac-
tion. The results were thresholded at P 5 .05 family
wise error (FWE)-corrected at the cluster level using a
cluster-building threshold of Puncorrected 5 0.001.
Data Analysis of Structural MRI
Cortical reconstruction and volumetric segmentation
were performed with Freesurfer software (version 5.3;
http://surfer.nmr.mgh.harvard.edu) using a standard
processing pipeline. The technical details of these proce-
dures have been previously described in detail.22,23 In
short, reconstruction procedures comprised intensity
normalization to Montreal Neurological Institute
(MNI)-space, skull stripping, filtering, segmentation,
and surface deformation. The quality of the skull strip-
ping and accuracy of the gray and white matter outer
boundaries were reviewed by a trained researcher
(S.L.), who was blinded to the grouping of the patients.
To extract the volumetric data of the predefined ROIs,
we used specialized Freesurfer tools for automated par-
cellation of gray and white matter.24 As in the resting-
state fMRI analysis, ROIs comprised bilateral SM1 (BA
1-4), SMA (bilateral BA 6), rIFG (BA 44 and 45), and
bilateral putamen. The extracted volume measures were
transformed into z scores for further analyses.
Predictions of Emerging LID
Measures reflecting dopaminergic modulation of
resting-state connectivity (n 5 4) and gray matter vol-
ume (n 5 6) were tested regarding their accuracy in clas-
sifying patients as LID or No-LID patients (Fig. 2A). We
applied a linear support vector classifier (C-SVC; c-value
5 1) implemented in LIBSVM v3.17, www.csie.ntu.edu.
tw/~cjlin/libsvm/ as described previously10 and used
leave-one-out cross-validation to compute classification
accuracy, sensitivity and specificity, and the receiver
operating characteristics (ROC) curve for computing the
area under the curve (AUC). We used permutation tests
(10,000 permutations) to derive the corresponding P val-
ues and applied Bonferroni-correction for multiple com-
parisons. Additional classifier analyses considered
resting-state connectivity measures from the OFF and
postlevodopa sessions separately.
Predictions of LID severity
We applied linear regression analyses to test whether
measures reflecting dopaminergic modulation of
resting-state connectivity predicted dyskinesia severity
of the LID patients (ie, Unified Dyskinesia Rating
Scale (UDysRS) scores as dependent variable). The
Bonferroni method was applied to correct for multiple
comparisons. One LID patient was detected as a sig-
nificant outlier (Grubbs test) and thus excluded.
Because patients with more severe LID also developed
dyskinesias more quickly (r 5 –0.608, P 5 .036, Pear-
son correlation), we additionally conducted partial
regression analyses using time to LID onset as a cova-
riate to account for individual differences in the time
between intake of levodopa and development of LID.
We conducted the same regression analyses with gray
matter volumes of ROIs. To assess whether putative
predictions were specific for the development of dyski-
nesias, we repeated the analyses using the individual
UPDRS OFF scores as a dependent variable.
Additional Control Analyses
Because head movements can affect the analysis of
resting-state connectivity, we calculated the number of
images moved more than 1 mm in relation to the previ-
ous image for each group and session.10 This analysis
revealed that only 0.58% of images showed movement
> 1 mm. Using this measure, head movements were not
different between groups or sessions (Effect of Group,
Session IA: P > .1). Furthermore, we measured respira-
tion and pulsation during resting-state fMRI acquisition
because drug-induced changes in these physiological
parameters can affect measures of resting-state connec-
tivity.25 Mean respiration frequency was 14/min 6 4
(SD) and mean pulse rate was 72/min 6 14, which was
not different between groups or sessions (Effect of
Group, Session IA: P > .1).
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Results
All LID patients developed dyskinesias after an
intake of 200 mg levodopa either inside the scanner
room or shortly after completion of MRI acquisition.
None of the No-LID patients developed dyskinesias.
In 7 LID patients, dyskinesias already emerged
between the first and second postlevodopa resting-
state fMRI. Therefore, only the resting-state fMRI
scan in the off state and the first postlevodopa resting-
state fMRI were used for analysis of resting-state con-
nectivity because they were available in all partici-
pants. The first postlevodopa resting-state fMRI was
acquired approximately 25 min after levodopa intake
(LID 23 6 3 min vs. No-LID 25 6 5 min, P >.1;
independent-sample t tests).
Dopaminergic modulation of resting-state connectiv-
ity between the SM1 and putamen in the most affected
hemisphere (classifier RS-1) significantly predicted
whether an individual patient would develop dyskine-
sias (P < .0001; Fig. 2B). Although resting-state con-
nectivity (both z-scored and non-z-scored covariance
estimates) between SM1 and the putamen increased
after levodopa intake in No-LID patients, it decreased
in LID patients. The classifier yielded 95.8% accuracy
corresponding to 1 false negative prediction (91.7%
sensitivity) and no false positive predictions (100%
specificity), which is illustrated in Figure 2C. The
other classifiers did not significantly differentiate
between patients with and without LID, and no
regions outside the considered ROIs showed a signifi-
cant Group 3 Dopamine interaction effect. Further-
more, volumetric MRI measures of the ROIs did not
significantly predict whether a patient would develop
LID. For a detailed description of the performance of
all classifiers, please see Table 2. Additional classifier
analyses, which only considered the OFF or postlevo-
dopa fMRI session, revealed that SM1–putamen
resting-state connectivity in the most affected hemi-
sphere before intake of levodopa (OFF) predicted LID
with an accuracy of 70.9% (83.3% sensitivity, 58.3%
specificity), but this result did not survive Bonferroni
correction for multiple comparisons (Puncorrected 5
.006, Pcorrected 5 .072). Other connectivity parameters
FIG. 2. Classifier analyses. A: List of classifiers. B: Classifier accuracy in distinguishing patients with and without levodopa-induced dyskinesias
(LID). C: Key parameters of the best classifier (SM1-putamen connectivity in most affected hemisphere). AUC, area under the curve; rIFG, right infe-
rior frontal gyrus; ROC, receiver-operating characteristic; RS, resting state; SM1, primary sensorimotor cortex; S, structural. [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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before or after levodopa intake did not predict emer-
gence of LID (Supplementary Table 1).
Acute dopaminergic modulation of resting-state con-
nectivity between the SMA and putamen predicted the
severity of LID (R2 5 0.627, P 5 .004). The more lev-
odopa decreased resting-state connectivity between the
SMA and putamen, the more pronounced were peak-
of-dose LID (Fig. 3). This was the case for both z-
scored and non-z-scored covariance estimates. Impor-
tantly, this result remained significant even when tak-
ing individual differences in the time to onset of LID
into account (R2 5 0.611, P 5 .008). There were no
other significant predictions of UDysRS- or UPDRS-
scores (all Puncorrected > .1). In contrast to resting-state
fMRI, regression analyses based on the volumetric
MRI data failed to predict LID severity after correc-
tion for multiple comparisons.
Discussion
We found a relation between dopaminergic modula-
tion of cortico-striatal resting-state connectivity and
peak-of-dose LID in patients with PD. First, dopami-
nergic modulation of resting-state connectivity
between the SM1 and putamen in the most affected
hemisphere differentiated LID and No-LID patients
with an accuracy of approximately 95%. Second,
dopaminergic modulation of SMA–putamen connectiv-
ity predicted LID severity. These results were not
mediated by volumetric changes in the predefined
ROIs.
The putamen is the main input structure of the basal
ganglia receiving cortical glutamatergic projections,
which are processed in the basal ganglia and sent back
to the same cortical areas in a closed-loop fashion.
Dopaminergic afferents from substantia nigra to the
putamen modulate these cortico-striatal projections,
which contribute to critical aspects of motor control
such as action selection, enhancement of motor vigor,
and habit formation.26,27 In PD, nigrostriatal degener-
ation leads to dopaminergic deafferentation of the
putamen causing impaired motor control. In line with
its central pathophysiological role, previous fMRI
studies consistently detected decreased motor-related
activation of the putamen in PD patients off medica-
tion, which is normalized by an intake of dopaminer-
gic drugs.28 During disease progression, however,
levodopa application leads to fluctuating and abnor-
mally elevated levels of striatal synaptic dopamine
because the ability to properly store and release
extrinsic dopamine into the synaptic cleft is lost.7,29,30
Crucially, such elevated levels of dopamine alter the
influence of cortical glutamatergic projections on
TABLE 2. Performance of classifiers
Cortical resting-state connectivity with putamen
Model Regions P Accuracy, % AUC
RS-1 Most affected SM1 <.0001 95.8 0.924
RS-2 Less affected SM1 .1 62.5 0.646
RS-3 SMA >.5 29.2 0.160
RS-4 rIFG >.1 54.2 0.444
Volumetric structural measures
Model Regions P Accuracy, % AUC
S-1 Most affected SM1 >.5 3.6 0
S-2 Less affected SM1 >.5 28.6 0.158
S-3 SMA >.5 0 0
S-4 rIFG >.5 0 0
S-5 Most affected putamen >.5 0 0
S-6 Less affected putamen >.1 50 0.418
Key parameters of the classification performance based on dopaminergic
modulation of resting-state connectivity and structural measures are listed
in the table. AUC, area under the curve; SM1, primary sensorimotor cortex;
rIFG, right inferior frontal gyrus.
FIG. 3. Dopaminergic modulation of resting-state connectivity between the SMA and putamen predict dyskinesia severity (P 5 .004). This relationship
was specific for the development of dyskinesias because dopaminergic modulation of SMA–putamen connectivity did not predict disease severity.
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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striatal activity through interactions with D1- and D2-
type receptors,31,32 leading to plastic changes in the
cortico-striatal synapse.33 This mechanism affects the
processing of motor signals in the direct and indirect
cortico-basal ganglia pathways, which is thought to
induce an abnormal facilitatory feedback signal to the
cortical areas resulting in the emergence of LID.9,33
In this study, abnormal dopaminergic modulation of
resting-state connectivity between the SM1 and puta-
men significantly predicted whether an individual
patient would develop dyskinesias. In LID patients,
resting-state connectivity between the SM1 and puta-
men decreased, whereas it increased in No-LID
patients after levodopa intake. This was only the case
for the most affected hemisphere, which is in agree-
ment with the observation that dyskinesias first
emerge on the side most affected by PD.10,34 Impor-
tantly, classification accuracy using resting-state SM1–
putamen connectivity in the OFF (70.9% accuracy) or
postlevodopa session (58.3%) separately was clearly
inferior to classification accuracy using dopaminergic
modulation of SM1–putamen connectivity (95.8%).
This finding highlights the usefulness of using pharma-
cological fMRI in LID patients. It also speaks against
the possibility that subclinical movements accounted
for the high classification accuracy because this should
also lead to high classification accuracy in the postle-
vodopa session where LID patients were on the verge
of developing dyskinesias. Although the physiological
significance of BOLD fluctuations during resting-state
is not entirely understood, it has been proposed that
they encode coordination and synchronization of
activity in interconnected neural areas.3 This suggests
that levodopa intake degrades the physiological orga-
nization of the SM1–putamen network in LID patients.
An abnormal dopaminergic modulation of SM1 in LID
patients has also been shown with transcranial mag-
netic stimulation (TMS). TMS studies targeting the
SM1 demonstrated aberrant changes in cortical plastic-
ity after levodopa intake in LID patients35,36 as well
as an alleviating effect of M1 stimulation on LID
severity.37,38
Levodopa-induced modulation of resting-state con-
nectivity between the SMA and putamen did not dis-
tinguish patients with and without LID (P > .5), but
it predicted LID severity (P 5 .004). The more levo-
dopa reduced resting-state connectivity between the
SMA and putamen, the more severely patients
expressed peak-of-dose dyskinesias. This finding is in
good agreement with our previous results obtained
with task-related fMRI in the same cohort.9,10 These
converging findings demonstrate the robustness of the
relationship between dopaminergic modulation of
SMA–putamen connectivity and LID severity across
different motor states (response inhibition and rest)
and analysis techniques (dynamic causal modeling and
covariance analysis). The relevance of SMA in deter-
mining LID severity is further supported by TMS stud-
ies over SMA showing beneficial effects on LID
severity in PD patients.39,40 The functional role of
dopaminergic modulation of cortico-striatal networks
in LID remains to be elucidated. The results of this
study suggest that SM1-putamen resting-state connec-
tivity is related to the all-or-nothing response to levo-
dopa,41 that is, it predicts whether a patient will
develop LID, whereas interindividual differences in
SMA–putamen connectivity predict LID severity.
Given that SMA and the adjacent pre-SMA are cen-
trally involved in inhibitory motor control, it is tempt-
ing to speculate that the ability of patients to control
the emerging involuntary movements, as indexed by
connectivity of the SMA–putamen network, deter-
mines LID severity. Such reversed inference, however,
has to be met with caution and needs to be explicitly
tested in future studies. At the behavioral level, one
might predict levodopa-induced deficits in inhibitory
motor control in LID patients. Furthermore, interven-
tional studies (eg, combined TMS-fMRI) might help to
disclose the causal contribution of distinct cortico-
striatal networks to the emergence of LID.
Although the rIFG is a key region for inhibitory
motor control,42,43 levodopa-induced modulation of
resting-state connectivity between the rIFG and puta-
men neither differentiated patients with and without
LID (P > .1) nor predicted LID severity. In contrast, a
recent study reported that rIFG resting-state connectiv-
ity with the putamen and SM1 was abnormally modu-
lated by dopamine in LID patients using rIFG as a
seed region.11 These findings are not necessarily in
contradiction to each other because we used anatomi-
cal masks for ROI definition instead of centering ROIs
on specific coordinates.11 Furthermore, a significant
difference at the group level does not entail significant
classification accuracy with respect to individual
patients. Of note, one previous study reported a signif-
icant classification accuracy distinguishing patients
with and without LID by measuring the structure of
the right inferior frontal sulcus.13 Importantly, the
parameter entered into the classifier was based on an
already known significant group difference in the same
patient group. Although such post hoc testing can be
of value to illustrate group differences at the individ-
ual subject level,10,13 it is problematic to use the same
data for selection and selective analysis.20 In this
study, we avoided this problem by using ROIs based
on previously reported differences between LID and
No-LID patients rather than using specific regions
based on group differences in the same resting-state
fMRI data set.
Limitations of the current study comprise the small
sample size and the absence of an independent valida-
tion cohort. Furthermore, in this cross-sectional study,
R E S T I N G - S T A T E F M R I P R E D I C T S D Y S K I N E S I A S
Movement Disorders, Vol. 31, No. 4, 2016 527
patients had already developed LID. Yet it would be
clinically highly relevant to assess whether a given PD
patient will develop LID in the future. In contrast to
task-related fMRI, resting-state fMRI does not require
patients to engage in a specific task and can be easily
standardized across imaging centers. Therefore,
levodopa-induced changes in resting-state connectivity
may serve as a powerful neuroimaging marker for
emerging LID in PD. Future studies in independent
validation cohorts and prospective studies are needed
to test whether resting-state fMRI can be used to iden-
tify patients at risk to develop LID. Different
approaches, such as seed-based11 or independent com-
ponent analyses,5,44 might both be valuable. In addi-
tion, using more well-defined anatomical regions (eg,
the foot area of the sensorimotor cortex in a patient
developing LID in the foot) might further strengthen
predictions of emerging LID based on resting-state
fMRI and improve the interpretability of the results.
Irrespective of the exact approach used for relating
resting-state fMRI to development of LID, we suggest
conducting pharmaco-fMRI including a levodopa chal-
lenge because the neural response to levodopa encodes
important information about a patient’s clinical
response.
References
1. Cilia R, Akpalu A, Sarfo FS, et al. The modern pre-levodopa era
of Parkinson’s disease: insights into motor complications from sub-
Saharan Africa. Brain 2014;137:2731-2742.
2. Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE.
Levodopa-associated dyskinesia risk among Parkinson disease
patients in Olmsted County, Minnesota, 1976–1990. Arch Neurol
2006;63:205-209.
3. Fox MD, Raichle ME. Spontaneous fluctuations in brain activity
observed with functional magnetic resonance imaging. Nat Rev
Neurosci 2007;8:700-711.
4. Rowe JB, Siebner HR. The motor system and its disorders. Neuro-
image 2012;61:464-477.
5. Szewczyk-Krolikowski K, Menke RA, Rolinski M, et al. Functional
connectivity in the basal ganglia network differentiates PD patients
from controls. Neurology 2014;83:208-214.
6. Barroso-Chinea P, Bezard E. Basal ganglia circuits underlying the
pathophysiology of levodopa-induced dyskinesia. Front Neuroanat
2010;4:131, doi:10.3389/fnana.2010.00131.
7. Cenci MA. Presynaptic mechanisms of l-DOPA-induced dyskinesia:
the findings, the debate, and the therapeutic implications. Front
Neurol 2014;5:242.
8. Cerasa A, Pugliese P, Messina D, et al. Prefrontal alterations in
Parkinson’s disease with levodopa-induced dyskinesia during fMRI
motor task. Mov Disord 2012;27:364-371.
9. Herz DM, Haagensen BN, Christensen MS, et al. Abnormal dopa-
minergic modulation of striato-cortical networks underlies levodopa-
induced dyskinesias in humans. Brain 2015;138:1658-1666.
10. Herz DM, Haagensen BN, Christensen MS, et al. The acute brain
response to levodopa heralds dyskinesias in Parkinson disease. Ann
Neurol 2014;75:829-836.
11. Cerasa A, Koch G, Donzuso G, et al. A network centred on the
inferior frontal cortex is critically involved in levodopa-induced
dyskinesias. Brain 2015;138:414-427.
12. Cerasa A, Messina D, Pugliese P, et al. Increased prefrontal volume
in PD with levodopa-induced dyskinesias: a voxel-based morphom-
etry study. Mov Disord 2011;26:807-812.
13. Cerasa A, Morelli M, Augimeri A, et al. Prefrontal thickening in
PD with levodopa-induced dyskinesias: new evidence from cortical
thickness measurement. Parkinsonism Relat Disord 2013;19:123-
125.
14. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Sys-
tematic review of levodopa dose equivalency reporting in Parkin-
son’s disease. Mov Disord 2010;25:2649-2653.
15. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A.
Pharmacodynamic modeling of oral levodopa: clinical application
in Parkinson’s disease. Neurology 1993;43:367-371.
16. Contin M, Riva R, Martinelli P, et al. Response to a standard oral
levodopa test in parkinsonian patients with and without motor
fluctuations. Clin Neuropharmacol 1990;13:19-28.
17. Zappia M, Colao R, Montesanti R, et al. Long-duration response
to levodopa influences the pharmacodynamics of short-duration
response in Parkinson’s disease. Ann Neurol 1997;42:245-248.
18. Nutt JG, Carter JH, Woodward WR. Effect of brief levodopa holi-
days on the short-duration response to levodopa: evidence for tol-
erance to the antiparkinsonian effects. Neurology 1994;44:1617-
1622.
19. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Auto-
mated anatomical labeling of activations in SPM using a macro-
scopic anatomical parcellation of the MNI MRI single-subject
brain. Neuroimage 2002;15:273-289.
20. Kriegeskorte N, Simmons WK, Bellgowan PS, Baker CI. Circular
analysis in systems neuroscience: the dangers of double dipping.
Nat Neurosci 2009;12:535-540.
21. Nachev P, Kennard C, Husain M. Functional role of the supple-
mentary and pre-supplementary motor areas. Nat Rev Neurosci
2008;9:856-869.
22. Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I.
Segmentation and surface reconstruction. Neuroimage 1999;9:179-
194.
23. Fischl B, Sereno MI, Dale AM. Cortical surface-based analysis. II:
Inflation, flattening, and a surface-based coordinate system. Neuro-
image 1999;9:195-207.
24. Desikan RS, Segonne F, Fischl B, et al. An automated labeling sys-
tem for subdividing the human cerebral cortex on MRI scans into
gyral based regions of interest. Neuroimage 2006;31:968-980.
25. Khalili-Mahani N, Chang C, van Osch MJ, et al. The impact of
“physiological correction” on functional connectivity analysis of
pharmacological resting state fMRI. Neuroimage 2013;65:499-510.
26. Redgrave P, Vautrelle N, Reynolds JN. Functional properties of
the basal ganglia’s re-entrant loop architecture: selection and rein-
forcement. Neuroscience 2011;198:138-151.
27. Robbins TW, Everitt BJ. A role for mesencephalic dopamine in
activation: commentary on Berridge (2006). Psychopharmacology
(Berl) 2007;191:433-437.
28. Herz DM, Eickhoff SB, Lokkegaard A, Siebner HR. Functional
neuroimaging of motor control in Parkinson’s disease: a meta-anal-
ysis. Hum Brain Mapp 2014;35:3227-3237.
29. de la Fuente-Fernandez R, Sossi V, Huang Z, et al. Levodopa-
induced changes in synaptic dopamine levels increase with progres-
sion of Parkinson’s disease: implications for dyskinesias. Brain
2004;127:2747-2754.
30. Pavese N, Evans AH, Tai YF, et al. Clinical correlates of
levodopa-induced dopamine release in Parkinson disease: a PET
study. Neurology 2006;67:1612-1617.
31. Bastide MF, Meissner WG, Picconi B, et al. Pathophysiology of L-
dopa-induced motor and non-motor complications in Parkinson’s
disease. Prog Neurobiol 2015;132:96-168.
32. Blanchet PJ, Calon F, Morissette M, et al. Relevance of the MPTP
primate model in the study of dyskinesia priming mechanisms. Par-
kinsonism Relat Disord 2004;10:297-304.
33. Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N, Picconi B.
Levodopa-induced dyskinesias in patients with Parkinson’s disease:
filling the bench-to-bedside gap. Lancet Neurol 2010;9:1106-1117.
34. Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease:
clinical manifestations. Mov Disord 2005;20(suppl 11):S11-S16.
35. Huang YZ, Rothwell JC, Lu CS, Chuang WL, Chen RS. Abnormal
bidirectional plasticity-like effects in Parkinson’s disease. Brain
2011;134:2312-2320.
H E R Z E T A L
528 Movement Disorders, Vol. 31, No. 4, 2016
36. Morgante F, Espay AJ, Gunraj C, Lang AE, Chen R. Motor cortex
plasticity in Parkinson’s disease and levodopa-induced dyskinesias.
Brain 2006;129:1059-1069.
37. Filipovic SR, Rothwell JC, van de Warrenburg BP, Bhatia K. Repeti-
tive transcranial magnetic stimulation for levodopa-induced dyskine-
sias in Parkinson’s disease. Mov Disord 2009;24:246-253.
38. Wagle-Shukla A, Angel MJ, Zadikoff C, et al. Low-frequency
repetitive transcranial magnetic stimulation for treatment of
levodopa-induced dyskinesias. Neurology 2007;68:704-705.
39. Brusa L, Versace V, Koch G, et al. Low frequency rTMS of the
SMA transiently ameliorates peak-dose LID in Parkinson’s disease.
Clin Neurophysiol 2006;117:1917-1921.
40. Koch G, Brusa L, Caltagirone C, et al. rTMS of supplementary
motor area modulates therapy-induced dyskinesias in Parkinson
disease. Neurology 2005;65:623-625.
41. Nutt JG, Holford NH. The response to levodopa in Parkinson’s
disease: imposing pharmacological law and order. Ann Neurol
1996;39:561-573.
42. Aron AR. From reactive to proactive and selective control: devel-
oping a richer model for stopping inappropriate responses. Biol
Psychiatry 2011;69:e55-e68.
43. Ridderinkhof KR, Forstmann BU, Wylie SA, Burle B, van den
Wildenberg WPM. Neurocognitive mechanisms of action con-
trol: resisting the call of the Sirens. WIREs Cogn Sci 2011;2:
174-192.
44. Niethammer M, Eidelberg D. Metabolic brain networks in transla-
tional neurology: concepts and applications. Ann Neurol 2012;72:
635-647.
Supporting Data
Additional Supporting Information may be found in
the online version of this article at the publisher’s
web-site.
R E S T I N G - S T A T E F M R I P R E D I C T S D Y S K I N E S I A S
Movement Disorders, Vol. 31, No. 4, 2016 529
